1198615-60-9

Usage

Uses

Used in Organic Synthesis:
Methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate is used as a building block in organic synthesis for the creation of complex organic molecules. Its versatility and stability contribute to its importance in this field.
Used in Pharmaceutical Research:
In Pharmaceutical Research, Methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate is used as a key intermediate in the development of new drugs. Its unique structure allows for the exploration of its potential in various therapeutic areas.
Used in Drug Development:
Methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate is used as a precursor in drug development, where its reactivity and structural features are leveraged to synthesize biologically active molecules with potential anti-cancer and anti-inflammatory properties.
Used in the Development of Biologically Active Molecules:
In the development of biologically active molecules, Methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate is used for its potential to contribute to the creation of compounds with significant therapeutic effects, underpinning its role in advancing pharmaceutical innovation.

Upstream product

• 20776-50-5 2-amino-4-bromobenzoic acid 
• 99277-71-1 4-bromo-2-nitrobenzoic acid 
• 158580-57-5 methyl 4-bromo-2-nitrobenzoate 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 73183-34-3 bis(pinacol)diborane 

Relevant academic research and scientific papers

Tetraphenylethylene-incorporated squaraine dyes: Structural and theoretical insights into the diverse emission behaviors in solution and solid state

Endowing organic dyes with desired emissive behaviors in diverse states is of great importance for broad practical applications, but it remains a huge challenge. In this study, based on the incorporation of tetraphenylethylene (TPE) into squaraine dyes, we successfully synthesized 2TPE-SQ and TPE-SQ and both exhibited dual state emission with emission efficiencies (ΦPL) up to 0.33 and 0.75, respectively. The intense emission in the crystalline state can be ascribed to highly restricted π-π stacking, while the different degrees of intramolecular phenyl motions in 2TPE-SQ and TPE-SQ result in weak and moderate emissions in solution. Combining density functional theory (DFT) calculations, local excited (LE)/twisted intramolecular charge transfer (TICT) and excited-state intramolecular proton transfer (ESIPT) mechanisms were proposed and accounted well for their very different emission wavelengths in solution and crystalline state, respectively. Besides, other emission behaviors such as aggregation-caused quenching (ACQ), crystalline-induced emission enhancement (CIEE) and thermo-/mechanochromism of these two derivatives were verified in detail, and all these results would bring a new insight into the investigation of organic luminogens in solution and solid state.

Self-Healing Hyper-Cross-Linked Metal-Organic Polyhedra (HCMOPs) Membranes with Antimicrobial Activity and Highly Selective Separation Properties

Fabrication of hybrid membranes composed of porous materials embedded in polymer matrices is a subject of topical interest. Herein, we introduce a new class of hybrid membranes: hyper-cross-linked metal-organic polyhedra (HCMOPs). These membranes are based upon soluble MOPs that can serve as high-connectivity nodes in hyper-cross-linked polymer networks. HCMOPs spontaneously form macro-scale, defect-free, freestanding membranes, and, thanks to the covalent cross-linking of MOPs, the resulting membranes possess multiple functionalities: strong water permeability; self-healing ability; antimicrobial activity; and better separation and mechanical performance than pristine polyimine membranes. This study introduces a new concept for the design and fabrication of multifunctional membranes and also broadens the applications of MOPs.

Rare Earth pcu Metal-Organic Framework Platform Based on RE4(μ3-OH)4(COO)62+ Clusters: Rational Design, Directed Synthesis, and Deliberate Tuning of Excitation Wavelengths

The Td point group symmetry of rare earth (RE3+) metal clusters RE4(μ3-OH)4(COO)62+ makes them attractive building blocks for creating metal-organic frameworks (MOFs) with controllable topologies. Herein, we describe the design and synthesis of a series of isoreticular MOFs featuring pcu topology [MOF-1114(RE) and MOF-1115(RE)] with variable rare earth metal ions (RE3+ = Y3+, Sm3+, Eu3+, Gd3+, Tb3+, Dy3+, Ho3+, Er3+, Tm3+, Yb3+) and linear amino-functionalized dicarboxylate linkers of different lengths. In total, we report 22 MOFs that vary in both composition and structure yet share the same RE4(μ3-OH)4 cluster motif. We demonstrate that these pcu MOFs are cationic and that anion exchange can be used to affect the MOF properties. We also investigate the luminescence properties of a representative member of this MOF series [MOF-1114(Yb)] that exhibits near-infrared emission. We show that the excitation energy for Yb3+ sensitization can be carefully adjusted to lower energy via covalent postsynthetic modification at the amino group sites within the MOF.

TRICYCLIC PYRIDONES AND PYRIMIDONES

A compound of Formula (I) is provided: (I) where the variables are defined herein.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

A pharmaceutical composition comprising the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is set forth. (Formula Ia), (Formula Ib), (Formula Ic), (Formula Id)

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:

4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF

Provided are compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.